Expression data from LNCaP cells treated with DHT and enzalutamide
Ontology highlight
ABSTRACT: Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. Here we used Affymetrix human genome microarray technology to investigate the global programme of gene expression of LNCaP cells in response to enzalutamide alone and in the context of DHT-stimulated androgen receptor gene expression.
ORGANISM(S): Homo sapiens
PROVIDER: GSE44905 | GEO | 2013/04/01
SECONDARY ACCESSION(S): PRJNA192516
REPOSITORIES: GEO
ACCESS DATA